Women in Appalachia have higher rates of late stage breast cancer

Sep. 26, 2013 — Older women living in the poorest areas of Appalachia in the U.S. fail to get regular breast cancer screening and have a higher incidence of later stage breast cancer, reports a new study in Health Services Research.

About 25 million people live in the 13 states that make up the Appalachian region, a 205,000-square-mile region that follows the spine of the Appalachian Mountains from southern New York to northern Mississippi. The National Cancer Institute has recently publicized Appalachia's higher rates of cancer and poorer outcomes for residents diagnosed with cancer.

To examine regional disparities in breast cancer screening and diagnosis, researchers evaluated Central Cancer Registry and Medicare claims data from three Appalachian states (Kentucky, Ohio, and Pennsylvania) to measure the incidence of later stage breast cancer in the region's poorest counties compared with its more affluent counties. The counties' economic statuses were compared based on factors such as unemployment rates, average home values and average monthly wages.

Women living in the most economically deprived counties -- located in eastern Kentucky and southeastern Ohio -- had 3.31 times as many late-stage tumors compared to those in the least deprived counties. Appalachian women in the study over age 65 had a 17.3 percent incidence of later stage breast cancer compared to a national average of 16 percent for women of the same age.

The degree of disparity between the counties was stronger than the researchers had suspected, said lead author Roger T. Anderson, Ph.D., from the department of public health science at Pennsylvania State University College of Medicine.

"Overall, we found counties that are struggling economically tend to have inadequate health care resources or infrastructure and have the highest rates of later-stage breast cancer," said Anderson.

There were also disparities in how often women received recommended mammography screening. Although area women over the age of 65 had Medicare insurance coverage, only 53 percent had mammography screening within the 2 years before their cancer diagnosis compared with the national average of 67 percent.

Anderson explained that counties that struggle economically may set up a "perpetuating cycle of few services to promote cancer prevention and early detection in communities and less overall use of preventive services."

Clement Gwede, Ph.D., associate director of diversity at the Moffitt Cancer Center in Tampa, agreed, saying that solutions to the disparities in late stage breast cancer in the nation's more distressed communities must include improved access to mammography screening resources, education and awareness, and related resources.

"Without these broad and sustained strategies, the vicious cycle will persist," Gwede added.

View the original article here

FDA Panel Backs Wider Use of Drug to Treat Early Stage Breast Cancer

THURSDAY, Sept. 12 (HealthDay News) -- U.S. advisers endorsed on Thursday the broader use of a drug already used to treat advanced breast cancer that also appears to shrink early stage breast tumors.

This could potentially offer women with early stage breast cancer a first-of-its-kind treatment option and the hope of less-invasive surgical procedures.

If approved to treat early stage tumors, the drug, Perjeta, might result in less invasive surgical treatment for women with HER2-positive early stage breast cancer. In that role, Perjeta (pertuzumab) would be the first cancer-fighting drug approved as a first-step breast cancer therapy in the United States.

A U.S. Food and Drug Administration advisory panel voted 13 to 0 to recommend approval of the drug. The FDA is not bound to follow the recommendations of its advisory panels but it usually does.

An FDA report that was posted online Tuesday said the drug looked promising in trials. The report also said, however, that drug-related cardiac concerns will require additional research.

Advisory panel chairman Dr. Mikkael Sekeres, a professor of medicine at the Cleveland Clinic, called Thursday's vote "a historic moment," The Associated Press reported.

"We are supporting the movement of a highly active drug for metastatic breast cancer to the first-line setting, with the hope that women with earlier stages of breast cancer will live longer and better," Sekeres said.

The FDA is considering "fast-track" -- or accelerated -- approval of Perjeta, which is made by Roche's Genentech division, the AP reported. Fast-track approvals usually are given to drugs that haven't been thoroughly tested but show promising results in early trials.

Panel members insisted Thursday that Genentech carry out more trials to ensure that Perjeta will enable breast cancer patients to live longer, healthier lives, the news service said.

Genentech estimated that about 15,000 women with HER2-positive early stage breast cancer could receive early treatment with Perjeta each year, Bloomberg News reported.

Cancer specialists welcomed the news earlier this week of the preliminary results for Perjeta.

"This is tremendously exciting," said Dr. Amy Tiersten, associate professor in the division of hematology and medical oncology at Mount Sinai Medical Center in New York City.

"Pertuzumab was FDA approved in 2012 for the treatment of metastatic breast cancer when it was shown that it improved survival when added to standard regimens for HER2-positive metastatic breast cancer," Tiersten said. Metastatic breast cancer is cancer that has spread to other parts of the body.

"But the really exciting information is when this can be translated into earlier stages of disease, where we can completely eradicate the disease and cure more women," she said.

The preliminary trial under discussion showed that when Perjeta was added to standard pre-surgical regimens for HER2-positive breast cancer, the chance of finding no cancer after the treatment was nearly doubled, Tiersten said.

Women who have chemotherapy before surgery and who achieve complete remission -- no cancer at the time of breast surgery -- have a much greater chance of being completely cured of their disease, she said.

Dr. Aye Moe Thu Ma, attending physician in breast surgical oncology with St. Luke's and Roosevelt Hospitals in New York City, also voiced enthusiasm.

"We currently have limited options for [first-step] treatment of breast cancer," Ma said. "I'm excited that this may provide a more specific treatment for people with HER2-positive cancer."

This means women may be able to keep their breasts because the tumor size is reduced before surgery, and some women may prefer this, she said.

Genentech is hoping for fast-track approval of Perjeta. The FDA can expedite approval for groundbreaking drugs as long as the drug maker pursues more research to show that the medication prolongs disease-free survival.

Both short- and long-term side effects will need to be examined to fully evaluate risks and benefits of this medication if it is approved, Ma added.

Perjeta is one of many newer biologic agents used to treat breast cancer. "These biologic or 'targeted' treatments work on breast cancer cells in a more specific way than some older treatments so there are many fewer casualties to normal cells translating into many fewer side effects for our patients," Tiersten said.

About one in eight women in the United States will develop breast cancer in her lifetime.

According to the Mayo Clinic, HER2-positive breast cancer is a breast cancer driven by a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells.

HER2-positive breast cancers typically are more aggressive than other types of breast cancer. But there are effective drug treatments, including trastuzumab (brand name Herceptin) and lapatinib (Tykerb). Both drugs can produce side effects, including congestive heart failure, according to the Mayo Clinic.

More information

The U.S. Department of Health and Human Services has more about early stage breast cancer.

Copyright c 2013?HealthDay. All rights reserved.

View the original article here

Immunology strengthens the fight against Colon Cancer Stage 4

Immunotherapy is undoubtedly a new medical strategy that evokes the human immune system to eradicate the disease. To summarize, in a span of 30 years, focusing the research conducted by both teams of doctors and scientists has shown that this approach is clinically successful for a wide range of diseases. Advances in adoptive immunotherapy, which focuses on expanding and infusion of specific disease-fighting white blood cells in patients, fast have followed this scientific arena its peak in terms of being an effective treatment for viral diseases, colon cancer, and surprisingly even stage 4 cancer types.

We can suppose, taking into consideration the reliable results and continuous progress, the importance of immunotherapy to grow exponentially-especially as it applies to late stage colon and other Stage 4 cancer. Currently, colon cancer stage 4 targets with little more than chemo and radiation, so the statistics are grim ... Renowned care providers do not dare report data of survival beyond the first couple of years as it is disappointing, with marginal promise.

New immunotherapy treatments, however, are inspiring as they provide an essential part of the puzzle-treatment with better overall results collaborated and quality of life for patients.

Envita leads the field in stage 4 Colon Cancer

A string of results published are shown the effects of adoptive immuno therapy in cancer patients. Dedicated medical team of Envita has evaluated the most reliable studies said and given the strengths and weaknesses of each. Their Immaculate research requires a protocol that incorporates only the most effective procedures for the extension and application of cells as a powerful immunotherapy. Our protocols are based on the latest published literature in the arena, by many hospitals and universities most prestigious both nationally and globally. Predictably, our treatment has been specially formulated specifically to treat colon cancer and immune systems of cancer patients in 4 phases.

Of Envita Colon Cancer 4 dual phase and immunotherapy of cancer 4th stage

Natural Envita Medical Center established in Mexico is using NK and CTL cells in real-time as immunotherapy for treatment of cancer and stage 4 colon cancer. Immune therapy of proprietary vaccine Envita appropriately is labelled AAIT\R (for immune system therapy autologous foster), and there are 4 main types of cells involved-the most significant being natural killer cells and T cells. The following are the types of cells that make up the treatment of Envita:

= > ‧ Natural killer cells
= > ‧ Natural killer t cells
‧ Cytokine Induced > = killer cells
= ‧ Cytotoxic T lymphocytes >

The being was created with the expansion of a patient's own immune cells in antitumor mega amounts. These cells are then analyzed for activation indicators and highlighted for their ability to destroy the colon cancer and other cells in the laboratory under controlled conditions, and then re-infused into the patient.

AAIT\R immunology available for Colon cancer and Stage 4 cancer patients to Mexico Envita

Natural Envita Medical Center is currently using T lymphocytes, NK and NKT as support for immunotherapy of cancer patients. Proprietary Envita vaccine stage 4 colon cancer is recorded as AAIT\R-one who increases a patient's own cancer cells of the immune system in the billions in a span of several weeks. These cells are evaluated for indicators, analysed for their ability to neutralize tumor cells stage 4 colon cancer in the lab and then eventually re-infused into the patient. Heralded by scientific research and clinical results of AAIT\R immunotherapy Enivta presents a valuable option for cancer patients who are acutely dedicated to conquering colon cancer stage 4 and others, while a intact immune system balance. Envita administers only top-level combinations of conventional cancer treatment and alternative accentuated by advanced cancer treatment natural help patients secure better health and improve the overall quality of life.

Understanding Stage 4 cancer is vital for those patients seeking remission of cancer at any stage. Recognizing necessary approaches, you will improve your chances of remission, the quality and length of life. Patients involved with the most comprehensive treatment plans always respond better to treatment. Let Envita better tailor prostate cancer Stage 4 treatment plan in place for you.

Use and distribution of this article is subject to our Publisher guidelines
whereby the original author and copyright information must be included.